Takeda's PhII meza­gi­ta­m­ab da­ta; Apogee's $483M raise; Gal­der­ma's IPO

Plus, news about Cy­bin, Mer­ck, Almi­rall, Eloxx Phar­ma­ceu­ti­cals and BioVie:

Take­da drug passed Phase II test: The pro­gram, meza­gi­ta­m­ab (TAK-079), is be­ing test­ed in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER